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Abstract
CONTEXT: Plasma brain natriuretic peptide (BNP) levels are elevated in patients with acute ischemic stroke, 
particularly when accompanied by atrial fibrillation (AF). Plasma BNP might be a useful marker of vulnerability to 
thromboembolism in non-valvular AF patients.
AIM: The aim of the present study was to assess whether the BNP level can serve as a biomarker of the left atrial 
(LA) thrombus in AF patients with acute ischemic stroke.
SETTINGS AND DESIGN: This was a multicenter prospective cohort study.
PATIENTS AND METHODS: Thirty AF patients with acute ischemic stroke were included in the study. Their 
transesophageal echocardiography (TEE) and BNP were assessed.
RESULTS: There was a positive significant relation between serum BNP levels and LA thrombus detection by TEE. 
BNP with a cutoff value >498 pg/l can be used as a diagnostic biomarker for the presence of the LA thrombus. 
A significant positive correlation existed between serum BNP and LA diameter. Furthermore, a statistically significant 
positive correlation between serum BNP and AF rate and duration was found in all patients. In addition, a statistically 
significant inverse correlation was detected between serum BNP and direct bilirubin, international normalized ratio, 
and albumin. A statistically significant positive correlation existed between serum BNP and prothrombin concentration.
CONCLUSION: BNP can be a good diagnostic biomarker for the detection of the LA thrombus in chronic AF patients 
with acute ischemic stroke.
Introduction
Atrial fibrillation (AF) patients with ischemic 
stroke or transient ischemic attacks (TIAs) are at high 
risk for recurrent stroke. Patients with the left atrial (LA) 
thrombus are at particularly high risk for thromboembolic 
events, the incidence of which can be reduced by 
anticoagulant agents.
Therefore, early identification of the LA 
thrombus in acute ischemic stroke is important to 
prevent further brain ischemia [1].
Although transesophageal echocardiography 
(TEE) is a useful clinical tool for identifying actual 
thrombi and visualizing spontaneous echo contrast 
in AF patients, its semi-invasive nature precludes its 
application for patients with acute stroke [2].
Brain natriuretic peptide (BNP) is 32 amino 
acids polypeptide with a 17 amino acid ring structure 
that was named after isolation from the porcine brain 
in 1988. It is a diuretic and vasodilatory factor that is 
released mainly from the ventricular myocardium. BNP 
was shown to be a sensitive marker of congestive heart 
failure. Plasma BNP levels are elevated in patients with 
acute ischemic stroke, particularly when accompanied 
by AF. Plasma BNP might be a useful marker of 
vulnerability to thromboembolism in non-valvular AF 
patients [3].
Aim of the work
The aim of the present study was to assess 
whether BNP levels can serve as a diagnostic biological 
marker of thrombus in AF patients with acute ischemic 
stroke. Study group – it consisted of 30 chronic AF 
patients who had acute ischemic stroke.
The study group was further divided into 
subgroups according to the results of TEE into either 
TEE positive or TEE negative. All participants were 
subjected to a full and careful history taking and clinical 
examination and echocardiography. Echocardiography 
was carried out using transthoracic echocardiography 
with M mode, two D mode, and Doppler study. In TEE, 
the key view is the two-chamber view to see the LA 
appendage (LAA), and it can be useful to study the 
appendage at ∼90° to this view to see the pectinate 
muscles in more details. The scan plane can be rotated 
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to ∼140° while maintaining the appendage in the center 
of the image [4].
Laboratory tests
Samples of BNP were withdrawn on the same 
day of doing TEE and were measured using the fluorescent 
immune-sorbent assay. The test principle is as follows:-
The microtiter plate provided in the kit comes 
pre-coated with an antibody specific to BNP. Samples 
are then added to the appropriate microtiter plate wells 
with a biotin-conjugated antibody specific to BNP. 
Next, avidin conjugated to horseradish peroxidase is 
added to each microplate well and incubated. After 
3,3′,5,5′-tetramethylbenzidine substrate solution is added, 
only those wells that contain BNP, biotin-conjugated 
antibody, and enzyme-conjugated avidin exhibit a change 
in color. The enzyme-substrate reaction is terminated by 
the addition of a sulfuric acid solution and the color change 
is measured spectrophotometrically at a wavelength of 
450 ± 10 nm. BNP concentration in the samples is then 
determined by comparing the optical density of the color 
of the samples to the standard curve [5].
Statistical data
Data were analyzed on an IBM computer using 
Statistical Package for the Social Sciences, version 12 
as follows:
(1) Quantitative variables were described as 
mean, standard deviation (SD), and range.
(2) Qualitative variables were described as 
number and percentage.
(3) The Chi-square-test was used to compare 
qualitative variables between groups.
(4) The unpaired t-test was used to compare 
quantitative variables, in parametric data (SD 
<50% mean).
(5) The one-way analysis of variance test was 
used to compare more than two groups as 
regard quantitative variables.
(6) Spearman’s correlation coefficient test was 
used to rank variables versus each other 
positively or inversely.
(7) Receiver operator characteristic curve was 
used to find out the best cutoff value and 
validity of a certain variable [6].
Results
There was a positive significant relation between 
serum BNP levels and presence of the LA thrombus, as 
documented by TEE. BNP with a cutoff value >498 pg/l 
can be used as a diagnostic biomarker for the presence 
of the LA thrombus. 
10
Control
30
PatientN =
4000
3000
2000
1000
0
-1000
BN
P 
(p
g/
L)
Group (pg/L)
Figure 1: Patients with transesophageal echocardiography (TEE)-
positive group having statistically significantly higher level of serum brain 
natriuretic peptide compared with the TEE-negative group (p < 0.001)
A significant positive correlation existed between 
serum BNP and LA diameter. In addition, a statistically 
significant positive correlation between serum BNP and 
AF rate and duration was found in all patients. 
Figure2: Correlation between serum brain natriuretic peptide levels 
and atrial fibrillation duration
A statistically significant inverse correlation 
was detected between serum BNP and direct bilirubin, 
international normalized ratio, and albumin. A statistically 
significant positive correlation existed between serum 
BNP and prothrombin concentration (Figures 1-4 and 
Tables 1-11).
Figure 3: Validity of serum brain natriuretic peptide in the prediction of 
transesophageal echocardiography result
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Discussion
The current study agrees with Okada et al. who 
were trying to find a relation between serum BNP levels 
and LA thrombus in chronic AF patients admitted with 
acute ischemic stroke (within 7 days) of an ischemic 
stroke or TIA, serum BNP was withdrawn at the day of 
TEE; the results were as follows: 
Figure 4: Validity of serum brain natriuretic peptide in the prediction of 
transesophageal echocardiography result
Table 1: Demographic data of patients
Variables Patient (%) Control (%) p-value
Gender
Female
Male
16 (53.33)
14 (46.67)
3 (30)
7 (70)
0.195
Age (Mean±SD) 58.7±10.462 28.7±5.774 <0.001*
SD: Standard deviation.
TEE-positive group (n = 17), serum BNP was 
higher compared with the TEE-negative group (n = 50) 
(307.3 ± 270.6 vs. 146.5 ± 119.5 pg/l, respectively) (p 
= 0.012).
Table 2: Distribution of the studied cases as regard clinical data
Clinical data n (%)
Smoking 14 (46.67)
IHD 8 (26.67)
HTN 14 (46.67)
DM 21 (70)
Dyslipidemia 21 (70)
DM: Diabetes mellitus, HTN: Hypertension, IHD: Ischemic heart disease.
Furthermore, they found that TEE-positive 
patients had statistically significant higher age than 
those of TEE-negative patients (76.5 ± 9.5 vs. 55.4 ± 
11.7 years, respectively) (p ≤ 0.001).
Table 3: Distribution of the studied patients as regard 
transesophageal echocardiography results (left atrial 
thrombus)
TEE n (%)
Negative 18 (60)
Positive 12 (40)
Total 30 (100)
TEE: Transesophageal echocardiography.
This comes in agreement with the findings of 
our study: The mean age in the TEE-positive group 
was 68.167 ± 9.20 years compared with 52.389 ± 
5.14 in the TEE-negative group (p < 0.001). A positive 
correlation existed between serum BNP and age 
(r = 0.562 and p < 0.001) [7].
Table 4: Serum brain natriuretic peptide in patients with acute 
ischemic stroke
Group BNP (pg/L)
Range Median Interquartile range Mean rank p-value
Patient 103.000–3557.000 322.500 1491.500 25.500 <0.001*
Control 8.00–63.000 27.000 45.500 5.500
BNP: Brain natriuretic peptide.
Doukky et al. conducted a retrograde cohort 
study of 297 consecutive cases with non-valvular AF 
who underwent a clinically indicated TEE for the LA 
thrombus detection. They aimed to investigate whether 
the plasma BNP is predictive of the LAA thrombus 
and stroke or not. Nineteen (6.4%) patients were 
found to have LA thrombus by TEE and the remaining 
278 (93.6%) were free of LA thrombus.
Table 5: Comparison between transesophageal echocardiography 
positive and negative groups as regard serum brain natriuretic 
peptide
Group BNP (pg/L) p-value
Range Mean±SD
Negative 103.000–489.000 237.611±112.014 <0.001*
Positive 825.000–43757 2125.333±1005.918
BNP: Brain natriuretic peptide.
There was a stepwise increase in the 
prevalence of the LA thrombus with an increasing BNP 
level. All patients with positive TEE had serum BNP of 
at least 500 pg/l and a decreased heart rate. However, 
in their study, there was no statistically significant 
difference as regard mean age in the TEE-positive 
group (n = 19) and the TEE-negative group (n = 278) 
(66 ± 13 vs. 62 ± 14 years, respectively) (p = 0.37) [8].
Table 6: Comparison between normal and abnormal left atrial 
diameter and serum brain natriuretic peptide
LA echo BNP (pg/L) p-value
Range Median Interquartile range Mean rank
Normal 103.000–195.000 118.000 56.000 4.000 <0.001*
Abnormal 218.000–3557.000 498.000 2050.000 19.000
BNP: Brain natriuretic peptide, LA: Left atrial.
Sakai et al. studied 221 patients (141 men; 
mean age: 72.9 years) to evaluate the role of BNP 
in distinguishing cardioembolic (CE) stroke from 
non-CE stroke. The median of the NIHSS score on 
admission was 6 (2–15.75). The mean ± SD time 
interval from stroke onset to blood sample collection 
was 8.2 ± 7.4 h, and the mean ± SD BNP level was 
214.5 ± 358.3 pg/ml.
B - Clinical Sciences Cardiology
122 https://www.id-press.eu/mjms/index
Table 11: Effect of LA diameter on the serum brain natriuretic 
peptide level according to the equation BNP=−6130.826+1476.889 
LA diameter, with R square of 76%
Model Unstandardized 
coefficients
Standardized 
coefficients
p-value R-square
B Std. error Beta
Constant −6130.826 763.304 <0.001* 76%
LA echo 1476.889 156.810 0.872 <0.001*
BNP: Brain natriuretic peptide, LA: Left atrial.
In agreement with the results of the present 
study, Doukky et al. [8] also showed that the BNP level 
had highly statistically significant positive correlation with 
LA size (coefficient r = 0.33 and p = 0.002). Moreover, 
Obel et al. showed that an increasing ventricular rate 
was associated with significantly lower peak inflow, 
peak outflow, mean inflow, and mean outflow velocities 
as well as with a lower time velocity interval of the LAA 
filling and emptying velocities. This effect was noted at 
rates of 60 beats/min compared with both 120 and 150 
beats/min [10], [11].
The findings of the present study were in 
agreement with those of Shimizu et al.; they assessed 
a possible relationship between LAA function and 
plasma BNP levels in non-valvular AF. The study 
consisted of 34 patients with chronic non-valvular AF 
(age: 69 ± 9 years) who underwent a TEE study and 
plasma BNP measurement. The patients were divided 
into two groups: Patients with and patients without a 
history of CE events (stroke) or echocardiographic 
evidence of thrombus into the embolic positive (E 
positive) group and the embolic negative (E negative) 
group, respectively. The patients of the E-positive group 
demonstrated greater impairment of the LAA velocity 
and higher plasma BNP levels than did those of the 
E-negative group. There was a statistically significant 
difference as regard LAA velocity (LAA velocity of 12 ± 
6 in the positive group vs. 31 ± 17 cm/s in the negative 
group, p < 0.05) [8], [12].
The findings of the current study were in 
agreement with those of Okada et al. who reported 
that the TEE-positive group had statistically significant 
higher serum BNP levels compared with the TEE-
negative group (307.3 ± 270.6 vs. 146.5 ± 119.5 pg/l, 
respectively; p = 0.012). This was in agreement with our 
results where a statistically significant difference was 
found between serum BNP in TEE-positive and TEE-
negative groups (2125.333 ± 1005.918 vs. 237.611 ± 
112.046 pg/l, respectively; p < 0.001) [7].
In addition, the findings of the present study 
were in agreement with those of Doukky et al. who 
found that serum BNP was highly elevated in patients 
with LA thrombus TEE positive (n = 19) compared with 
patients with LA thrombus TEE negative (n = 278), with 
a statistically significant difference (1949 ± 1787 vs. 819 
± 1067 pg/l, respectively; p = 0.001). They concluded 
that the serum BNP level is predictive of LA thrombus 
in patients with non-valvular AF and may have a better 
discriminatory capacity than that of the CHADS2 and 
CHADS2-VASc [8].
Table 7: Correlation between serum brain natriuretic peptide 
and age, left atrial diameter, atrial fibrillation duration, and atrial 
fibrillation rate
Correlations BNP (pg/L) 
R p-value
Age (years) 0.562 0.001*
LA echo 0.872 <0.001*
AF (duration) 0.902 <0.001*
HR (beat/min) 0.955 <0.001*
HR: Heart rate, AF: Atrial fibrillation, LA: Left atrial.
According to the results of BNP, they divided 
the patients into two groups: The high BNP level group, 
which included 81 (36.7%) patients and the low BNP 
level group, which included 140 (63.3%) patients. They 
found that the patients of the high BNP level group 
were of CE origin, mostly AF with variable types. They 
also found that there was a statistically significant 
difference between the high BNP level (CE positive) 
group and the low BNP level (CE negative) group as 
regard age (77.7 ± 12.0 vs. 70.1 ± 12.0, respectively) 
(p < 0.001) [9].
Table 8: Correlation between serum brain natriuretic peptide 
and laboratory data
Correlations BNP (pg/L)
R p-value
Bil T (mg/dL) −0.350 0.058*
Bil D (mg/dL) −0.392 0.032*
PT (s) −0.348 0.059*
INR −0.373 0.042*
PC (%) 0.442 0.014*
Uric acid (mg/dL) 0.350 0.058*
Albumin (g/dL) −0.760 <0.001*
BNP: Brain natriuretic peptide.
Okada et al. [6] found no effect of sex on the 
stroke or thrombus formation or the serum BNP level.
Table 9: Validity of serum brain natriuretic peptide in the 
prediction of transesophageal echocardiography result
ROC curve
Cutoff Sens. Spec. PPN NPV Accuracy
>498* 91.7 100.0 100.0 94.7 0.954
That BNP is considered highly valid in prediction with the left atrial thrombus, with sensitivity of 91% at cutoff 
value 498 pg. NPV: Negative predictive value, PPV: Positive predictive value, ROC: Receiver operating 
characteristic.
However, Sakai et al. found a significant 
difference as regard sex between the high and low BNP 
level groups. The frequency of the female sex in the 
high BNP group was 44.4% compared with 31.4% for 
the low BNP group (p < 0.001) [9].
Table 10: Effect of atrial fibrillation duration on the serum 
level of brain natriuretic peptide according to the equation 
BNP=−406.764+230.681 AF duration, with the R square of 81%
Model Unstandardized 
coefficients
Standardized 
coefficients
p-value R-square
B Std. error Beta
Constant −406.764 155.577 0.014* 81.4%
AF (duration) 230.681 20.852 0.902 <0.001*
BNP: Brain natriuretic peptide, AF: Atrial fibrillation.
In their study, Okada included 17 TIA patients, 
with a mean age of 76.5 + 11.1 years. There was a 
positive correlation (r = 0.872) between LA diameter 
and serum BNP levels with p < 0.001. This means that 
serum BNP is elevated with the LA dilatation, which 
increased the risk for LA thrombus [7].
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Sakai et al. found that the patients in the high 
BNP group were of CE in origin, mostly AF with variable 
types. CE occurred in 59 (72.8%) patients in the high 
BNP group (n = 81) and in 17 (12.1%) patients in the 
low BNP group (n = 140), with p < 0.001 [8].
Of the 21 patients without CE who had high 
BNP levels, seven had chronic renal failure, five had old 
myocardial infarction, and two were cardiomyopathic 
(22 patients of high BNP group were of non-CE stroke 
and 123 patients of the low BNP group were of non-CE 
stroke). A BNP level of 142.5 pg/ml was identified as 
the optimal cutoff value with a sensitivity of 77.6% 
and specificity of 84.8%. This is in agreement with the 
findings of the present study; however, a higher cutoff 
level of more than 498 pg/ml increased sensitivity to 
91.7% and specificity to 100% [9].
Shimizu et al. reported that the atrium is the 
main source of BNP in AF patients without overt heart 
failure. Thirteen chronic non-valvular AF patients with 
a history of CE events (stroke) or echocardiographic 
evidence of thrombus (E-positive group) were compared 
with 21 AF patients without complications (neither 
echocardiographic evidence of the LA thrombus nor 
any CE events) (E-negative group). The result of their 
study showed that the patients of the E-positive group 
demonstrated greater impairment of the LAA velocity 
and higher plasma BNP levels than did those of the 
E-negative group. Their study showed a statistically 
significant difference as regard serum BNP between 
the two groups (126 ± 53 vs. 86 ± 45 ng/l; p < 0.05). 
They concluded that BNP was a significant predictor of 
thromboembolism. This is in agreement with our results; 
a statistically significant difference was detected in our 
study between serum BNP in TEE-positive and TEE-
negative groups (2125.333 ± 1005.918 vs. 237.611 ± 
112.046 pg/l, respectively; p < 0.001). Moreover, our 
results were in agreement with those of Maruyama et al. 
who studied 231 patients with acute ischemic stroke. 
The highest serum BNP level was found in patients 
with CE stroke due to AF. The BNP levels positively 
correlated with CHADS2 scores in AF patients (202 
[120–385 pg/l]) with p < 0.001 [12], [13].
The results of the current study were in 
agreement with those of Zhixin et al. who studied 142 
acute ischemic stroke patients and made their discharge 
diagnosis and stroke etiologic subtypes according 
to TOAST criteria: LAA, CE, small artery occlusion, 
stroke of other determined etiology, and stroke of other 
undetermined etiology. Of the 142 patients, 35.92% 
were diagnosed with LAA at discharge, 25.35% with 
CE, 27.46% with small artery occlusion, and 11.27% 
with stroke of other determined etiology or stroke of 
other undetermined etiology. Age, previous cardiac 
disease, AF, length of the stay, NIHSS on admission, 
and modified Rankin score on discharge were all 
significantly higher in the CE patients compared with 
those of other subtypes (p < 0.01). Moreover, the mean 
BNP concentration was significantly higher in the CE 
group than those of other subtypes (p < 0.001). The 
optimal cutoff value, sensitivity, and specificity of the 
plasma BNP concentration suitable to distinguish 
CE from non-CE were 66.5 pg/l, 75.0%, and 88.7%, 
respectively [14]. This study showed a good positive 
correlation among the study groups between serum 
BNP and AF duration with p < 0.001 and r = 0.902. 
A possible explanation could be that with increased 
AF duration, the LA becomes more and more dilated 
because of remodeling. The LA is the main source of 
BNP in chronic AF, and thus, its level increases with 
time.
Conclusion
BNP can be used as a good diagnostic 
biomarker for the presence of the LA thrombus in 
chronic non-valvular AF intensive care unit patients 
admitted with acute ischemic stroke.
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